论文部分内容阅读
目的:观察孟鲁司特钠在小儿咳嗽变异型哮喘治疗中的临床疗效。方法:选取我院在2011年12月~2012年12月收治的78例小儿咳嗽变异型哮喘患者作为研究对象,随机分为两组:对照组39例,均给予沙丁胺醇、布地纳德喷雾常规治疗;实验组39例,其在给予常规治疗基础上,联合孟鲁司特钠进行治疗。比较两组患者治疗后的不良反应情况及临床疗效。结果:实验组患者的总有效率为97.4%,显著高于对照组(87.2%),P<0.05。在治疗过程中,对照组发生不良反应5例(12.8%),实验组发生1例(2.6%),实验组的不良反应发生率显著低于对照组,P<0.05。结论:鲁司特钠联合沙丁胺醇、布地纳德治疗小儿咳嗽变异型哮喘,具有疗效显著、不良反应少的优点,它是一种安全有效的治疗方法,值得在临床治疗中加以推广。
Objective: To observe the clinical efficacy of montelukast sodium in the treatment of children with cough variant asthma. Methods: A total of 78 pediatric cough variant asthma patients treated in our hospital from December 2011 to December 2012 were selected and randomly divided into two groups: control group, 39 patients were given salbutamol, Budenad spray routine treatment ; Experimental group of 39 patients, on the basis of conventional treatment, combined with montelukast sodium for treatment. The adverse reactions and clinical effects of the two groups after treatment were compared. Results: The total effective rate of the experimental group was 97.4%, significantly higher than that of the control group (87.2%), P <0.05. In the course of treatment, 5 cases (12.8%) of adverse reactions occurred in the control group, 1 case (2.6%) occurred in the experimental group, and the incidence of adverse reactions in the experimental group was significantly lower than that of the control group (P <0.05). Conclusion: The combination of Lustrate sodium and albuterol and budenad in the treatment of infantile cough variant asthma has the advantages of significant curative effect and less adverse reactions. It is a safe and effective treatment and should be popularized in clinical treatment.